Galderma Pharma to acquire Spirig Pharma

Spirig, focused on skin conditions, had sales of $106 million in 2011

LAUSANNE, Switzerland — Swiss skin drug maker Galderma Pharma will acquire another Swiss drug maker also focused on treatments for skin conditions, Galderma said.

Based in Egerkingen, Switzerland, Spirig makes treatments for such conditions as solar damage and skin barrier function impairment, as well as treatments for such precancerous conditions as actinic keratosis. Financial terms of the deal were not disclosed, though it was noted that Spirig had sales of about $106 million in 2011. The global corporate headquarters of Galderma will remain in Lausanne, Switzerland.

"We are excited about our two companies' commercial and geographic opportunities, maximizing the value of our complementary product portfolios in the prescription and self-medication markets," Galderma VP business development and markets Albert Draaijer said. "We look forward to welcoming Spirig employees and to combining our efforts to better meet the market's needs."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.